Ixekizumab and Malignant Neoplasms
JAMA Dermatology · 01.10.2025 · 161 (10) · 1048
DOI: 10.1001/jamadermatol.2025.2056 ↗Kurz gefasst
Fachartikel in der Zeitschrift JAMA Dermatology, erschienen am 01.10.2025. Verfasst von Joseph F Merola und 15 weiteren Autor:innen. Beteiligte Einrichtung: UT Southwestern Medical Center, Dallas, Texas. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Importance Assessing malignant neoplasm risk among patients with long-term biologic exposure is of interest. This study provides insight into the risk of malignant neoplasm among patients with psoriasis (PsO), psoriatic arthritis (PsA), or axial spondyloarthritis (axSpA) who received ixekizumab (IXE) over time.
Objective
To determine the incidence of malignant neoplasms among patients with PsO, PsA, or axSpA who received long-term (up to 6 years) IXE treatment, and to compare the recorded incidences (excluding nonmelanoma skin cancer) with those observed in the US general population. Design, Setting, and Participants This multicenter, global pooled analysis examined patient data from 25 randomized clinical trials (RCTs) in patients with PsO, PsA, or axSpA receiving at least 1 dose of IXE over 5 years (PsO) or 3 years (PsA and axSpA). Eligibility criteria varied across the 25 RCTs, but most of the patients were naive to biologic treatments. The primary analysis was performed in March 2021 (PsA) and March 2022 (PsO and axSpA).
Intervention
Long-term treatment with IXE. Main Outcomes and Measures Incidence rates of malignant neoplasms and standardized incidence ratios (SIRs).
Results
The mean age across the 3 indications was 45.9 years; most patients in the PsO and axSpA cohorts were male (4696/6892 [68.1%] and 650/932 [69.7%], respectively), whereas the proportion of male to female patients in the PsA cohort was largely balanced (679/1401 [48.5%] vs 722/1401 [51.5%], respectively). The study included 6892 patients with PsO, 1401 patients with PsA, and 932 patients with axSpA, representing a cumulative exposure to IXE of 22 371.1 patient-years (PY) (18 025.7 PY for PsO, 2247.7 PY for PsA, and 2097.7 PY for axSpA). Malignant neoplasms were reported among 141 patients with PsO (2.0%; incidence rate [IR], 0.8 per 100 PY [95% CI, 0.7-0.9]), 15 patients with PsA (1.1%; IR, 0.7 per 100 PY [95% CI, 0.4-1.1]), and 9 patients with axSpA (1.0%; IR, 0.4 per 100 PY [95% CI, 0.2-0.8]). IRs of malignant neoplasms at 1-year intervals remained low (≤1.2 per 100 PY) and constant over time. SIRs with 95% CIs were below or near 1 (PsO, 0.89 [95% CI, 0.71-1.08]; PsA, 0.49 [95% CI, 0.13-0.85]; axSpA, 1.07 [95% CI, 0.37-1.77]). Conclusions and Relevance This pooled analysis of 25 RCTs demonstrated that the safety profile of IXE supports long-term use in patients with PsO, PsA, or axSpA. This is evidenced by incidences of malignant neoplasms consistent with previous reports, and with SIRs of malignant neoplasms across indications similar to the US general population.
Autor:innen und Institutionen
- UT Southwestern Medical Center, Dallas, Texas.
- Probity Medical Research and Alliance Clinical Trials, Waterloo, Ontario, Canada.
- Division of Dermatology, Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.
- Oregon Health & Science University, Portland.
- Blauvelt Consulting, Portland, Oregon.
- Eli Lilly and Company, Indianapolis, Indiana.
Zitieren
APA
Merola, J. F., Papp, K. A., Deodhar, A., Blauvelt, A., Kronbergs, A., Feely McDonald, M., Eberhart, N., Zhu, D., Inman, E., Grace, E., Holzkaemper, T., Rahman, P., Marzo-Ortega, H., Gottlieb, A. B., Schwartzman, S., & Lebwohl, M. (2025). Ixekizumab and Malignant Neoplasms. JAMA Dermatology, 161(10), 1048. https://doi.org/10.1001/jamadermatol.2025.2056
Vancouver
Merola JF, Papp KA, Deodhar A, Blauvelt A, Kronbergs A, Feely McDonald M, et al. Ixekizumab and Malignant Neoplasms. JAMA Dermatology. 2025;161(10):1048. doi:10.1001/jamadermatol.2025.2056
BibTeX
@article{Merola2025,
author = {Merola, Joseph F and Papp, Kim A and Deodhar, Atul and Blauvelt, Andrew and Kronbergs, Andris and Feely McDonald, Meghan and Eberhart, Nadezdha and Zhu, Danting and Inman, Elsa and Grace, Elsie and Holzkaemper, Thorsten and Rahman, Proton and Marzo-Ortega, Helena and Gottlieb, Alice B and Schwartzman, Sergio and Lebwohl, Mark},
title = {Ixekizumab and Malignant Neoplasms},
journal = {JAMA Dermatology},
year = {2025},
volume = {161},
number = {10},
pages = {1048},
doi = {10.1001/jamadermatol.2025.2056}
}
EUVIMED